Trial Profile
A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 08 Apr 2023 As per NCT main page the sponsor is "Mitsubishi Tanabe Pharma Corporation" but according to compare view it is showing as "Mitsubishi Tanabe Pharma America" and I am keeping the associations as per NCT.
- 03 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2009 Planned end date changed from Dec 2008 to Feb 2009 as reported by ClinicalTrials.gov.